The life sciences market was not immune to macroeconomic trends in 2022. The rising cost of capital, slumping stock market, geopolitical tension, and decades-high inflation all weighed on the industry. General investor sentiment, across asset classes and industries, shifted to a risk-off mindset that clearly affected venture capital (VC) funding and the IPO market.
What hasn’t changed are the underlying fundamentals of the life sciences industry. As the U.S. population ages, there is an increasing need for medical care and discovery. And continued technological advancements are opening the door for customized or individualized care and treatment for patients. Meanwhile, the tremendous investment in the life sciences in recent years comes with a clear need for the talent so incredibly important to this industry.
Download the report.